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Abstract 
Purpose: To investigate the long-term visual prognosis and progression of 
chorioretinal atrophy in patients with myopic choroidal neovascularization 
(mCNV) treated with intravitreal injections of Bevacizumab. 
Methods: Hospital-based, retrospective cross sectional study. In total, 22 
patients (22 eyes) with treatment-naïve mCNV who underwent intravitreal 
injection of bevacizumab and were followed up for more than 48 months were 
investigated. Visual acuity and fundus photographs before and 1, 2, 3, and 4 
years after initial treatment in the clinics were compared and judged if 
chorioretinal atrophy (CRA) developed/enlarged or remained unchanged. The 
influence of clinical characteristics including age, sex, axial length, baseline 
visual acuity, CNV area, CNV location, and number of injections were 
investigated with logistic regression analysis. 
Results: Mean logarithm of the minimum angle of resolution (logMAR) improved 
from 0.76 to 0.52 (P < .01), 0.48 (P < .01), and 0.54 (P < .05) after 1, 2, and 3 
years, respectively. The effect slightly declined to marginally non-significant 
levels after 4 years (logMAR, 0.59; P = .07). CRA developed or enlarged in 9 
cases (41%) in 1 year, reaching 16 cases (73%) at the final visit. Those without 
CRA enlargement achieved better visual improvement. None of the 
aforementioned patient characteristics significantly affected CRA. 
Conclusions: Anti-VEGF therapy for mCNV is effective for vision improvement 
in the long term. On the other hand, development or enlargement of CRA 
frequently occurred and affected visual improvement. Strategies to manage 




Pathologic myopia is one of the major causes of visual impairment worldwide. 
The disease, marked by elongation of axial length and changes in the fundus of 
the eye, may cause complications such as posterior staphyloma, chorioretinal 
atrophy (CRA), or choroidal neovascularization (CNV). Considering that myopia 
is more prevalent in younger populations,[1, 2] the impact on social health will be 
more profound in the near future. 
 Myopic CNV (mCNV) is reported to occur in up to 10% of myopic 
patients,[3] with a prevalence of up to 40% in highly myopic patients.[4] Since 
long-term visual prognosis is poor in the absence of treatment,[5, 6] a wide 
range of therapeutic alternatives, including photocoagulation, macular 
translocation, surgical CNV removal, administration of triamcinolone acetonide, 
and photodynamic therapy (PDT), have been explored.[7] Although PDT can 
stabilize the disease activity, formation of subretinal fibrosis[8] or CRA, a cause 
of the poor natural course of mCNV,[6, 9] frequently occurs after the 
treatment,[10] and may affect visual function significantly in the long term. In fact, 
the most reliable trial (Verteporfin In Photodynamic Therapy: VIP study) failed to 
show significant improvement in vision 2 years after the treatment.[11] 
 After the PDT era, anti-vascular endothelial growth factor (VEGF) 
therapy was developed and proved to be effective against mCNV.[12-24] 
Although the treatment regimens were not equivalent in these studies, 
intravitreal anti-VEGF therapy seems to promote the regression of CNV more 
effectively and decrease the frequency of CRA, compared to PDT.[25-28] 
However, even with anti-VEGF therapy, CRA still develops[17, 18, 24, 25] and 
may affect the long-term visual prognosis. [24] In fact, vision improvement 
became non-significant in some of these studies by the end of 2 years of 
follow-up.[17, 29-31] Although a recent report showed favorable effects after 3 
years of follow-up,[32] some of the studied subjects had previously been treated 
with PDT. Thus, long-term prognosis of anti-VEGF therapy, especially for 
treatment-naïve mCNV, is still unclear. 
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 In the present study, we investigated long-term visual prognosis of 
treatment-naïve mCNV patients who underwent anti-VEGF therapy. We also 
investigated how often CRA progression occurs in these patients, and explored 
the difference between those with and without CRA enlargement. 
 
Methods 
All procedures conformed to the tenets of the Declaration of Helsinki and 
were approved by the Institutional Review Board at Kyoto University Graduate 
School of Medicine. Written informed consent was obtained from each patient. 
We retrospectively reviewed the clinical records of mCNV patients. 
Inclusion criteria were as follows: 1) presence of subfoveal or juxtafoveal CNV, 
2) refractive error greater or equal to -6.0 diopters or axial length greater or equal 
to 26.5 mm, 3) underwent intravitreal injection of 1.25 mg bevacizumab at Kyoto 
University Hospital, and 4) no previous ocular surgery other than 
phacoemulsification and aspiration for cataract. When both eyes of one patient 
met the inclusion criteria, only the right eye was included. Exclusion criteria 
were: 1) any treatment for mCNV other than anti-VEGF therapy prior to or during 
the observation period, 2) a follow-up period of less than 48 months, and 3) 
intraocular surgery or development of other ocular diseases during the follow-up. 
 Initial and follow-up fluorescein angiography (FA) was performed with a 
confocal scanning laser ophthalmoscope (HRA2; Heidelberg Engineering, 
Heidelberg, Germany), and 45-degree fundus photographs are taken with a 
fundus camera (TRC NW6S; TOPCON, Tokyo, Japan). Injections of 1.25 mg 
bevacizumab were performed under sterile conditions, and prophylactic topical 
antibiotics were applied from a few days before to 1 week after the injection. 
Follow-up intervals were 1, 3, 6, 12, 18, 24, 30, 36, and 48 months. Additional 
follow-up was planned for each patient at the clinician’s discretion. Visual acuity, 
funduscopic examination, and optical coherence tomography (OCT) 
examination were performed at each visit. FA was performed when subjective 
symptoms worsens but OCT does not show obvious exudative changes. After 
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the initial treatment, additional treatment was applied as needed. The need for 
re-treatment was determined according to objective/subjective decline of vision, 
exudative changes in OCT images, and/or dye leakage in FA. Same dose of 
Bevacizumab had been injected for re-treatment until December, 2008 when we 
encountered the outbreak of aseptic endophthalmitis. [33] Thereafter, 0.3 mg of 
Pegaptanib had been used for five months. Then after use of Ranibizumab was 
officially approved in May 2009, 0.5 mg of Ranibizumab was applied for the 
recurrences. 
 Development or enlargement of CRA was judged with photographs 
taken each year by 2 of the authors (AO and KY) who were blinded to the other 
characteristics of the patient. The judgment was based on changes in patchy 
atrophy; color changes in tessellation or diffuse atrophy without patchy atrophy 
were not considered as CRA progression (Figure 1). CRAs, which were not 
adjacent to original CNV location, were not counted. When the 2 authors 
disagreed, a third author (AT) was asked to arbitrate. The CNV area was 
manually measured in early-phase FA images with measuring tools, which were 
coupled to the HRA2. Location of CNV was judged from FA; those involving the 
center of the foveal avascular area on FA were judged as subfoveal. When it was 
difficult to judge only from FA images, OCT images were used to confirm 
whether CNV membranes lied beneath the fovea. 
 Statistical analyses were conducted using IBM SPSS Statistics Desktop 
(version 19.0; IBM Japan, Tokyo, Japan). Descriptive analyses were recorded as 
means ± standard deviation unless otherwise specified. The BCVA was 
measured based on a Landolt C chart and then converted to logarithm of the 
minimal angle of resolution (logMAR) equivalents. Differences in VA from 
baseline were analyzed using repeated measures ANOVA with post-hoc Tukey’s 
test. Logistic regression analysis of the clinical variables was performed with 
development/enlargement of CRA as the dependent variable. Independent 
variables were chosen based on forward stepwise regression. Correlations 
between the variables were also evaluated with Spearman rank correlation. 
Differences in age, axial length, BCVA, and number of injections between those 
Formatted: Underline
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with and without CRA progression were evaluated with Mann–Whitney U-test. 
Chi-square test was applied to assess the difference in sex or CNV location 
(subfovea/juxtafovea) between those with and without CRA progression. 
 
Results 
 Forty eyes of 40 patients met the inclusion criteria. Two patients had 
bilateral involvement but only their right eyes were included. We excluded one 
patient who developed aseptic endophthalmitis, one who developed central 
retinal vein occlusion, 2 who underwent vitrectomy for retinoschisis, and 4 who 
underwent additional PDT. Ten patients dropped out before the end of the 48 
months of follow-up. Finally, 22 eyes of 22 patients were eligible for the study. 
Among them, 7 were men and 15 were women. The mean age of the 
participants was 64.1 ± 9.6 years (range, 47 to 81 years), and axial length was 
28.9 ± 1.6 mm (range, 26.28 to 32.63 mm). The refractive error of phakic 
patients was -11.9 ± 3.7 diopter (range, -7 to -21). Mean number of injections 
was 2.1 ± 1.9 (range, 1 to 7) including 41 times of Bevacizumab and six times of 
Ranibizumab injections. 
 Development or enlargement of CRA was noted in 9 eyes (40.9%) in 1st 
year, 14 eyes (63.6%) in 2nd years, and 16 eyes (72.7%) in 3rd and 4th years; 
those without CRA progression after 3 years did not show remarkable change in 
the fourth year. Logistic regression analysis showed non-significant effect of age 
(P = .08) and location of CNV for CRA progression at 1 year (P = .07). After 2 
years, none of the parameters showed significant effect. Table 1 shows 
characteristics of those with and without CRA progression at 4 years after the 
treatment. Visual improvement was better in those without CRA progression 
than those with CRA progression. Those without CRA progression tended to 
include juxtafoveal CNV more frequently but the difference was not significant (P 
= .21). Representative cases are shown in Figures 1–5. Some patients 
developed CRA early after the treatment (Figure 1), whereas others developed 
CRA after 1 or 2 years (Figure 2). The minority of patients was free of CRA 
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progression during the course of the 48-month follow-up (Figure 3). 
 Visual acuity improved from baseline but slightly declined thereafter. The 
difference from baseline was significant until 3 years and was marginally 
insignificant at 4 years after the treatment (Figure 4). Among the baseline CNV 
characteristics, CNV size measured with FA image was associated with visual 
improvement (r=.434, P=.04); larger CNV resulted in poor visual improvement. 
 
Discussion 
 We investigated long-term visual outcome and progression of CRA in 
treatment-naïve mCNV patients who underwent anti-VEGF therapy. The study 
showed significant improvement of vision over the 3 years of follow-up, despite 
that the P value was barely non-significant in the fourth year, and confirmed the 
beneficial effect of anti-VEGF therapy for mCNV. At the same time, the study 
showed that most patients finally experience the progression of CRA irrespective 
of baseline characteristics, and that CRA compromises the vision-improving 
effect. 
 Anti-VEGF therapy is becoming a standard treatment for mCNV 
although its application is not yet officially approved in many countries. The 
present study confirmed the long-term effect of the therapy. Considering that the 
effect of PDT is limited to maintain vision,10,[34] anti-VEGF therapy should be the 
first choice until a novel method is proven to be more effective. 
 On the other hand, the present study raised some concerns regarding 
longer-term prognosis: the progression of CRA. Anti-VEGF therapy is 
considered to be superior to PDT partly because it induces CRA less frequently. 
However, the present result showed that the assumption is not necessarily 
applicable in the long term. In fact, CRA developed or enlarged in as many as 
80% of the patients. Even considering that only 3/10 dropout patients showed 
CRA progression at their final visit, the percentage of patients with CRA 
progression should be at least [(16 + 3)/(22 + 10)]  100 = 59.4%. This figure is 
comparable to the 70% in PDT-treated eyes after 4 years,[10] or the 77.8% 
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(35/45 eyes) in eyes after the natural course of 5 years[35] but not to the 95.1% 
reported for the 80 months result.[36] Hence, CRA progression is often an 
inevitable consequence in the long-term follow-up of mCNV cases, probably due 
to natural history but to anti-VEGF therapy. Considering that those with CRA 
progression showed less visual improvement, the control of CRA should be the 
next step to be investigated. 
 Older age has been associated with development of CRA[36] or poor 
visual outcome.[37],[38] However, the present study did not show significant 
contribution of age for the development of CRA. One explanation could be the 
existence of a critical age. Most of the previous studies investigated 
age-dependent differences by comparing aged and younger patients of 40 to 60 
years of age. The population in the present study consisted of relatively older 
subjects; the average and median age of the participants in the present study 
was 64.1 and 64 years, respectively. A small percentage of young patients could 
explain the non-significant effect of age. 
 The location of CNV is of clinical interest. Several groups, including ours, 
showed that patients with juxtafoveal CNV have better prognosis than subfoveal 
CNV during the natural course of the disease[35] or after anti-VEGF therapy.[18, 
39] Moreover, subfoveal CNV induces larger CRA after PDT than do juxtafoveal 
or extrafoveal CNV[10] or induce CRA more frequently after intravitreal injection 
of Bevacizumab.[24] In the present study, subfoveal CNV tended to cause CRA 
progression more frequently at 1 year after the initial treatment, although this 
was not statistically significant. Furthermore, 4 out of 6 patients who were free of 
CRA for 4 years had juxtafoveal CNV. The statistical non-significance may be 
partly due to the small sample size and the difficulty in treating recurrent cases: 
one case with juxtafoveal CNV recurred with subfoveal CNV and developed CRA 
thereafter. Although the underlying mechanism is not clear, e.g., could subfoveal 
CNV be a mere result of larger CNV size?, whether the location of CNV can be a 
practical prognostic parameter of CRA progression should be further 
investigated. 
 There still is a debate about which protocol is the most effective. Some 
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authors used 3 monthly injections at the loading phase, whereas others adopted 
a single injection followed by additional as-needed injections. The dose of the 
drug also varies among reports, with 1, 1.25, and 2.5 mg of bevacizumab having 
been reported to be effective. Although we cannot draw any conclusion from the 
non-comparative study, we prefer the single injection and as-needed regimen 
due to lower risk and smaller cost, considering the relatively young age, healthier 
RPE, and slower progression of mCNV[40] compared to age-related macular 
degeneration. Randomized or meta-analysis study should be conducted to 
address the issue. 
 There are several limitations to the present study, including its 
retrospective design, uncontrolled examination interval, small sample size, and 
lack of a control group. In addition, there have existed a selection bias, e.g., 
patients with persistent or recurrent CNV would more likely present to the 
hospital for a longer period or, conversely, patients with severe phenotypes might 
have undergone additional PDT and be excluded from the study. In addition, we 
did not investigate OCT images in detail because the resolution of the devices 
used when the patients underwent initial treatment was limited. Further 
evaluation of pretreatment OCT image including retinal layer thickness or 
choroidal thickness would be interesting. These points should be noted when 
interpreting the results. 
 In conclusion, we showed that anti-VEGF therapy had satisfactory 
vision-improving effect for a 4-year period but the treatment was not free of 
inducing CRA. To achieve better results, the causes and management of CRA 
should be further investigated. 
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Figure 1. Color fundus photographs of a representative case with subfoveal 
choroidal neovascularization (CNV) (left, pretreatment; triangle, CNV). Patchy 
atrophy was not evident after 1 year (middle) but developed thereafter (right, 48 
months after the treatment; arrow, CRA). 
 
Figure 2. Color fundus photographs and fluorescein angiography image of a 
62-year-old woman. She had subfoveal CNV (upper left and middle panels; 
triangle, CNV) and was administered 2 bevacizumab injections. Chorioretinal 
atrophy (arrows) developed as early as 1 year after treatment (upper right) and 
progressed further thereafter (lower left, middle, and right panels: 2, 3, and 4 
years, respectively). Her visual acuity, calculated as logMAR, improved from 
0.15 to 0.4 in 1 year but declined to 0.2 in the subsequent year, ultimately 
reaching 0.08. 
 
Figure 3. Color fundus photographs and fluorescein angiography image of a 
77-year-old woman. She had juxtafoveal mCNV (upper left and middle panels; 
triangle) and her left visual acuity, calculated as logMAR, was 0.1. mCNV 
diminished with an intravitreal injection of bevacizumab, and chorioretinal 
atrophy was not evident initially (upper right,1 year after treatment). However, 
CNV recurred in 20 months (lower left; triangle) and after 6 additional injections, 
chorioretinal atrophy (arrows) developed and enlarged (lower middle and right 
panels: 3 and 4 years, respectively). Finally, her visual acuity was 0.05. 
 
Figure 4. Color fundus photographs and fluorescein angiography image of a 
74-year-old man with juxtafoveal mCNV and visual acuity of 0.3 (upper left and 
middle panels, triangle). With a single injection of bevacizumab, mCNV 
efficiently regressed (upper right, 1 year after the treatment). Although the 
peripapillary atrophy enlarged within this period, mCNV-related chorioretinal 
atrophy was not noted (lower left, middle, and right panels: 2, 3, and 4 years 
 15 
after treatment, respectively), and favorable improvement in vision was achieved 
(final visual acuity was 0.9). 
 
Figure 5. Changes in visual acuity as a function of time. Dot plots represent 
mean values, and whiskers represent 95% confidence intervals. Visual acuity 
improvement was roughly maintained during the 4-year period despite the p 
value being barely non-significant in the fourth year. * P < .05 and ** P < .01 




TABLE 1. Characteristics of patients with and without chorioretinal atrophy 
progression 4 years after intravitreal injection of bevacizumab. 
 CRA Non-CRA P value 
Age (years) 63.5 ± 10.7 65.7 ± 6.3 n.s. 
Sex (male/female) 5/11 2/4 n.s. 
Axial length (mm) 29.06 ± 1.52 28.32 ± 1.96 n.s. 
Baseline logMAR 
(unit) 
0.76 ± 0.38 0.76 ± 0.22 n.s. 
Final logMAR (unit) 0.67 ± 0.51 0.38 ± 0.39 n.s. 
Visual improvement 0.10 ± 0.34 -0.37 ± 0.33 P = .049 
Area of CNV (mm2) 1.55 ± 1.21 1.03 ± 0.79 n.s. 
Location of CNV 
(subfovea/juxtafovea) 
10/6* 2/4 n.s. 
Number of injections 2.1 ± 1.7 2.2 ± 2.4 n.s. 
CRA: chorioretinal atrophy progression; logMAR: logarithm of the minimum 
angle of resolution; CNV: chorioretinal atrophy 
*One eye with juxtafoveal CNV showed recurrence involving the subfovea. 
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Abstract 
Purpose: To investigate the long-term visual prognosis and progression of 
chorioretinal atrophy in patients with myopic choroidal neovascularization 
(mCNV) treated with intravitreal injections of Bevacizumab. 
Methods: Hospital-based, retrospective cross sectional study. In total, 22 
patients (22 eyes) with treatment-naïve mCNV who underwent intravitreal 
injection of bevacizumab and were followed up for more than 48 months were 
investigated. Visual acuity and fundus photographs before and 1, 2, 3, and 4 
years after initial treatment in the clinics were compared and judged if 
chorioretinal atrophy (CRA) developed/enlarged or remained unchanged. The 
influence of clinical characteristics including age, sex, axial length, baseline 
visual acuity, CNV area, CNV location, and number of injections were 
investigated with logistic regression analysis. 
Results: Mean logarithm of the minimum angle of resolution (logMAR) improved 
from 0.76 to 0.52 (P < .01), 0.48 (P < .01), and 0.54 (P < .05) after 1, 2, and 3 
years, respectively. The effect slightly declined to marginally non-significant 
levels after 4 years (logMAR, 0.59; P = .07). CRA developed or enlarged in 9 
cases (41%) in 1 year, reaching 16 cases (73%) at the final visit. Those without 
CRA enlargement achieved better visual improvement. None of the 
aforementioned patient characteristics significantly affected CRA. 
Conclusions: Anti-VEGF therapy for mCNV is effective for vision improvement 
in the long term. On the other hand, development or enlargement of CRA 
frequently occurred and affected visual improvement. Strategies to manage 




Pathologic myopia is one of the major causes of visual impairment worldwide. 
The disease, marked by elongation of axial length and changes in the fundus of 
the eye, may cause complications such as posterior staphyloma, chorioretinal 
atrophy (CRA), or choroidal neovascularization (CNV). Considering that myopia 
is more prevalent in younger populations,[1, 2] the impact on social health will be 
more profound in the near future. 
 Myopic CNV (mCNV) is reported to occur in up to 10% of myopic 
patients,[3] with a prevalence of up to 40% in highly myopic patients.[4] Since 
long-term visual prognosis is poor in the absence of treatment,[5, 6] a wide 
range of therapeutic alternatives, including photocoagulation, macular 
translocation, surgical CNV removal, administration of triamcinolone acetonide, 
and photodynamic therapy (PDT), have been explored.[7] Although PDT can 
stabilize the disease activity, formation of subretinal fibrosis[8] or CRA, a cause 
of the poor natural course of mCNV,[6, 9] frequently occurs after the 
treatment,[10] and may affect visual function significantly in the long term. In fact, 
the most reliable trial (Verteporfin In Photodynamic Therapy: VIP study) failed to 
show significant improvement in vision 2 years after the treatment.[11] 
 After the PDT era, anti-vascular endothelial growth factor (VEGF) 
therapy was developed and proved to be effective against mCNV.[12-24] 
Although the treatment regimens were not equivalent in these studies, 
intravitreal anti-VEGF therapy seems to promote the regression of CNV more 
effectively and decrease the frequency of CRA, compared to PDT.[25-28] 
However, even with anti-VEGF therapy, CRA still develops[17, 18, 24, 25] and 
may affect the long-term visual prognosis. [24] In fact, vision improvement 
became non-significant in some of these studies by the end of 2 years of 
follow-up.[17, 29-31] Although a recent report showed favorable effects after 3 
years of follow-up,[32] some of the studied subjects had previously been treated 
with PDT. Thus, long-term prognosis of anti-VEGF therapy, especially for 
treatment-naïve mCNV, is still unclear. 
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 In the present study, we investigated long-term visual prognosis of 
treatment-naïve mCNV patients who underwent anti-VEGF therapy. We also 
investigated how often CRA progression occurs in these patients, and explored 
the difference between those with and without CRA enlargement. 
 
Methods 
All procedures conformed to the tenets of the Declaration of Helsinki and 
were approved by the Institutional Review Board at Kyoto University Graduate 
School of Medicine. Written informed consent was obtained from each patient. 
We retrospectively reviewed the clinical records of mCNV patients. 
Inclusion criteria were as follows: 1) presence of subfoveal or juxtafoveal CNV, 
2) refractive error greater or equal to -6.0 diopters or axial length greater or equal 
to 26.5 mm, 3) underwent intravitreal injection of 1.25 mg bevacizumab at Kyoto 
University Hospital, and 4) no previous ocular surgery other than 
phacoemulsification and aspiration for cataract. When both eyes of one patient 
met the inclusion criteria, only the right eye was included. Exclusion criteria 
were: 1) any treatment for mCNV other than anti-VEGF therapy prior to or during 
the observation period, 2) a follow-up period of less than 48 months, and 3) 
intraocular surgery or development of other ocular diseases during the follow-up. 
 Initial and follow-up fluorescein angiography (FA) was performed with a 
confocal scanning laser ophthalmoscope (HRA2; Heidelberg Engineering, 
Heidelberg, Germany), and 45-degree fundus photographs are taken with a 
fundus camera (TRC NW6S; TOPCON, Tokyo, Japan). Injections of 1.25 mg 
bevacizumab were performed under sterile conditions, and prophylactic topical 
antibiotics were applied from a few days before to 1 week after the injection. 
Follow-up intervals were 1, 3, 6, 12, 18, 24, 30, 36, and 48 months. Additional 
follow-up was planned for each patient at the clinician’s discretion. Visual acuity, 
funduscopic examination, and optical coherence tomography (OCT) 
examination were performed at each visit. FA was performed when subjective 
symptoms worsens but OCT does not show obvious exudative changes. After 
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the initial treatment, additional treatment was applied as needed. The need for 
re-treatment was determined according to objective/subjective decline of vision, 
exudative changes in OCT images, and/or dye leakage in FA. Same dose of 
Bevacizumab had been injected for re-treatment until December, 2008 when we 
encountered the outbreak of aseptic endophthalmitis. [33] Thereafter, 0.3 mg of 
Pegaptanib had been used for five months. Then after use of Ranibizumab was 
officially approved in May 2009, 0.5 mg of Ranibizumab was applied for the 
recurrences. 
 Development or enlargement of CRA was judged with photographs 
taken each year by 2 of the authors (AO and KY) who were blinded to the other 
characteristics of the patient. The judgment was based on changes in patchy 
atrophy; color changes in tessellation or diffuse atrophy without patchy atrophy 
were not considered as CRA progression (Figure 1). CRAs, which were not 
adjacent to original CNV location, were not counted. When the 2 authors 
disagreed, a third author (AT) was asked to arbitrate. The CNV area was 
manually measured in early-phase FA images with measuring tools, which were 
coupled to the HRA2. Location of CNV was judged from FA; those involving the 
center of the foveal avascular area on FA were judged as subfoveal. When it was 
difficult to judge only from FA images, OCT images were used to confirm 
whether CNV membranes lied beneath the fovea. 
 Statistical analyses were conducted using IBM SPSS Statistics Desktop 
(version 19.0; IBM Japan, Tokyo, Japan). Descriptive analyses were recorded as 
means ± standard deviation unless otherwise specified. The BCVA was 
measured based on a Landolt C chart and then converted to logarithm of the 
minimal angle of resolution (logMAR) equivalents. Differences in VA from 
baseline were analyzed using repeated measures ANOVA with post-hoc Tukey’s 
test. Logistic regression analysis of the clinical variables was performed with 
development/enlargement of CRA as the dependent variable. Independent 
variables were chosen based on forward stepwise regression. Correlations 
between the variables were also evaluated with Spearman rank correlation. 
Differences in age, axial length, BCVA, and number of injections between those 
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with and without CRA progression were evaluated with Mann–Whitney U-test. 
Chi-square test was applied to assess the difference in sex or CNV location 
(subfovea/juxtafovea) between those with and without CRA progression. 
 
Results 
 Forty eyes of 40 patients met the inclusion criteria. Two patients had 
bilateral involvement but only their right eyes were included. We excluded one 
patient who developed aseptic endophthalmitis, one who developed central 
retinal vein occlusion, 2 who underwent vitrectomy for retinoschisis, and 4 who 
underwent additional PDT. Ten patients dropped out before the end of the 48 
months of follow-up. Finally, 22 eyes of 22 patients were eligible for the study. 
Among them, 7 were men and 15 were women. The mean age of the 
participants was 64.1 ± 9.6 years (range, 47 to 81 years), and axial length was 
28.9 ± 1.6 mm (range, 26.28 to 32.63 mm). The refractive error of phakic 
patients was -11.9 ± 3.7 diopter (range, -7 to -21). Mean number of injections 
was 2.1 ± 1.9 (range, 1 to 7) including 41 times of Bevacizumab and six times of 
Ranibizumab injections. 
 Development or enlargement of CRA was noted in 9 eyes (40.9%) in 1st 
year, 14 eyes (63.6%) in 2nd years, and 16 eyes (72.7%) in 3rd and 4th years; 
those without CRA progression after 3 years did not show remarkable change in 
the fourth year. Logistic regression analysis showed non-significant effect of age 
(P = .08) and location of CNV for CRA progression at 1 year (P = .07). After 2 
years, none of the parameters showed significant effect. Table 1 shows 
characteristics of those with and without CRA progression at 4 years after the 
treatment. Visual improvement was better in those without CRA progression 
than those with CRA progression. Those without CRA progression tended to 
include juxtafoveal CNV more frequently but the difference was not significant (P 
= .21). Representative cases are shown in Figures 1–5. Some patients 
developed CRA early after the treatment (Figure 1), whereas others developed 
CRA after 1 or 2 years (Figure 2). The minority of patients was free of CRA 
 6 
progression during the course of the 48-month follow-up (Figure 3). 
 Visual acuity improved from baseline but slightly declined thereafter. The 
difference from baseline was significant until 3 years and was marginally 
insignificant at 4 years after the treatment (Figure 4). Among the baseline CNV 
characteristics, CNV size measured with FA image was associated with visual 
improvement (r=.434, P=.04); larger CNV resulted in poor visual improvement. 
 
Discussion 
 We investigated long-term visual outcome and progression of CRA in 
treatment-naïve mCNV patients who underwent anti-VEGF therapy. The study 
showed significant improvement of vision over the 3 years of follow-up, despite 
that the P value was barely non-significant in the fourth year, and confirmed the 
beneficial effect of anti-VEGF therapy for mCNV. At the same time, the study 
showed that most patients finally experience the progression of CRA irrespective 
of baseline characteristics, and that CRA compromises the vision-improving 
effect. 
 Anti-VEGF therapy is becoming a standard treatment for mCNV 
although its application is not yet officially approved in many countries. The 
present study confirmed the long-term effect of the therapy. Considering that the 
effect of PDT is limited to maintain vision,10,[34] anti-VEGF therapy should be the 
first choice until a novel method is proven to be more effective. 
 On the other hand, the present study raised some concerns regarding 
longer-term prognosis: the progression of CRA. Anti-VEGF therapy is 
considered to be superior to PDT partly because it induces CRA less frequently. 
However, the present result showed that the assumption is not necessarily 
applicable in the long term. In fact, CRA developed or enlarged in as many as 
80% of the patients. Even considering that only 3/10 dropout patients showed 
CRA progression at their final visit, the percentage of patients with CRA 
progression should be at least [(16 + 3)/(22 + 10)]  100 = 59.4%. This figure is 
comparable to the 70% in PDT-treated eyes after 4 years,[10] or the 77.8% 
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(35/45 eyes) in eyes after the natural course of 5 years[35] but not to the 95.1% 
reported for the 80 months result.[36] Hence, CRA progression is often an 
inevitable consequence in the long-term follow-up of mCNV cases, probably due 
to natural history but to anti-VEGF therapy. Considering that those with CRA 
progression showed less visual improvement, the control of CRA should be the 
next step to be investigated. 
 Older age has been associated with development of CRA[36] or poor 
visual outcome.[37],[38] However, the present study did not show significant 
contribution of age for the development of CRA. One explanation could be the 
existence of a critical age. Most of the previous studies investigated 
age-dependent differences by comparing aged and younger patients of 40 to 60 
years of age. The population in the present study consisted of relatively older 
subjects; the average and median age of the participants in the present study 
was 64.1 and 64 years, respectively. A small percentage of young patients could 
explain the non-significant effect of age. 
 The location of CNV is of clinical interest. Several groups, including ours, 
showed that patients with juxtafoveal CNV have better prognosis than subfoveal 
CNV during the natural course of the disease[35] or after anti-VEGF therapy.[18, 
39] Moreover, subfoveal CNV induces larger CRA after PDT than do juxtafoveal 
or extrafoveal CNV[10] or induce CRA more frequently after intravitreal injection 
of Bevacizumab.[24] In the present study, subfoveal CNV tended to cause CRA 
progression more frequently at 1 year after the initial treatment, although this 
was not statistically significant. Furthermore, 4 out of 6 patients who were free of 
CRA for 4 years had juxtafoveal CNV. The statistical non-significance may be 
partly due to the small sample size and the difficulty in treating recurrent cases: 
one case with juxtafoveal CNV recurred with subfoveal CNV and developed CRA 
thereafter. Although the underlying mechanism is not clear, e.g., could subfoveal 
CNV be a mere result of larger CNV size?, whether the location of CNV can be a 
practical prognostic parameter of CRA progression should be further 
investigated. 
 There still is a debate about which protocol is the most effective. Some 
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authors used 3 monthly injections at the loading phase, whereas others adopted 
a single injection followed by additional as-needed injections. The dose of the 
drug also varies among reports, with 1, 1.25, and 2.5 mg of bevacizumab having 
been reported to be effective. Although we cannot draw any conclusion from the 
non-comparative study, we prefer the single injection and as-needed regimen 
due to lower risk and smaller cost, considering the relatively young age, healthier 
RPE, and slower progression of mCNV[40] compared to age-related macular 
degeneration. Randomized or meta-analysis study should be conducted to 
address the issue. 
 There are several limitations to the present study, including its 
retrospective design, uncontrolled examination interval, small sample size, and 
lack of a control group. In addition, there have existed a selection bias, e.g., 
patients with persistent or recurrent CNV would more likely present to the 
hospital for a longer period or, conversely, patients with severe phenotypes might 
have undergone additional PDT and be excluded from the study. In addition, we 
did not investigate OCT images in detail because the resolution of the devices 
used when the patients underwent initial treatment was limited. Further 
evaluation of pretreatment OCT image including retinal layer thickness or 
choroidal thickness would be interesting. These points should be noted when 
interpreting the results. 
 In conclusion, we showed that anti-VEGF therapy had satisfactory 
vision-improving effect for a 4-year period but the treatment was not free of 
inducing CRA. To achieve better results, the causes and management of CRA 
should be further investigated. 
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Figure 1. Color fundus photographs of a representative case with subfoveal 
choroidal neovascularization (CNV) (left, pretreatment; triangle, CNV). Patchy 
atrophy was not evident after 1 year (middle) but developed thereafter (right, 48 
months after the treatment; arrow, CRA). 
 
Figure 2. Color fundus photographs and fluorescein angiography image of a 
62-year-old woman. She had subfoveal CNV (upper left and middle panels; 
triangle, CNV) and was administered 2 bevacizumab injections. Chorioretinal 
atrophy (arrows) developed as early as 1 year after treatment (upper right) and 
progressed further thereafter (lower left, middle, and right panels: 2, 3, and 4 
years, respectively). Her visual acuity, calculated as logMAR, improved from 
0.15 to 0.4 in 1 year but declined to 0.2 in the subsequent year, ultimately 
reaching 0.08. 
 
Figure 3. Color fundus photographs and fluorescein angiography image of a 
77-year-old woman. She had juxtafoveal mCNV (upper left and middle panels; 
triangle) and her left visual acuity, calculated as logMAR, was 0.1. mCNV 
diminished with an intravitreal injection of bevacizumab, and chorioretinal 
atrophy was not evident initially (upper right,1 year after treatment). However, 
CNV recurred in 20 months (lower left; triangle) and after 6 additional injections, 
chorioretinal atrophy (arrows) developed and enlarged (lower middle and right 
panels: 3 and 4 years, respectively). Finally, her visual acuity was 0.05. 
 
Figure 4. Color fundus photographs and fluorescein angiography image of a 
74-year-old man with juxtafoveal mCNV and visual acuity of 0.3 (upper left and 
middle panels, triangle). With a single injection of bevacizumab, mCNV 
efficiently regressed (upper right, 1 year after the treatment). Although the 
peripapillary atrophy enlarged within this period, mCNV-related chorioretinal 
atrophy was not noted (lower left, middle, and right panels: 2, 3, and 4 years 
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after treatment, respectively), and favorable improvement in vision was achieved 
(final visual acuity was 0.9). 
 
Figure 5. Changes in visual acuity as a function of time. Dot plots represent 
mean values, and whiskers represent 95% confidence intervals. Visual acuity 
improvement was roughly maintained during the 4-year period despite the p 
value being barely non-significant in the fourth year. * P < .05 and ** P < .01 




TABLE 1. Characteristics of patients with and without chorioretinal atrophy 
progression 4 years after intravitreal injection of bevacizumab. 
 CRA Non-CRA P value 
Age (years) 63.5 ± 10.7 65.7 ± 6.3 n.s. 
Sex (male/female) 5/11 2/4 n.s. 
Axial length (mm) 29.06 ± 1.52 28.32 ± 1.96 n.s. 
Baseline logMAR 
(unit) 
0.76 ± 0.38 0.76 ± 0.22 n.s. 
Final logMAR (unit) 0.67 ± 0.51 0.38 ± 0.39 n.s. 
Visual improvement 0.10 ± 0.34 -0.37 ± 0.33 P = .049 
Area of CNV (mm2) 1.55 ± 1.21 1.03 ± 0.79 n.s. 
Location of CNV 
(subfovea/juxtafovea) 
10/6* 2/4 n.s. 
Number of injections 2.1 ± 1.7 2.2 ± 2.4 n.s. 
CRA: chorioretinal atrophy progression; logMAR: logarithm of the minimum 
angle of resolution; CNV: chorioretinal atrophy 
*One eye with juxtafoveal CNV showed recurrence involving the subfovea. 
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